0.05),but these positive rates were notable decreased comparing with nPCR and immunohistochemistry techniques(P

The incidence rate is high in Asia country, accounting for 15 %-20 % of Non-Hodgkin lymphoma. Every phynotype has different heterogeneity, therapeutic effect and prognosis are also different. There is no standard rigemen for T cell lymphoma at present. CHOP like regimen is commonly used. But therapeutic effect is not as good as we expected. Clinical research shows that dose and intensity regimen, such as m-BACOD,ProMACE-CytaBOM, MACOP-B, do not exhibit survival advantage compared with CHOP regimen. New treatment includes cytotoxic drug, such as gemcitabine. As first line therapy for T cell lymphoma or as salvage therapy for refractory or relapsed T cell lymphoma, the therapeutic effect is good. Gemcitabine based regimen is new for PTCL. Alemtuzumab is a humanized CD52 mono-clonal antibody and is expected as good effect on PTCL therapy. Zanolimumab is a humanized mono-clonal antibody which targets CD4 antigen on T cell. Phase Ⅱclinical research has also got good effect. Denileukin difiitox and Pralatrexate also have good effect on PTCL therapy in clinical researches. Autologous stem cell transplantation(ASCT) is also used in PTCL therapy.

Objective To investigate the clinical features and prognostic factors of nasal type NIGT cell lymphoma(NKTCL).Methods Records of 61 patients with pathologically confirmed nasal type NKTCL were reviewed.Detailed clinical and laboratory data were included in univariate analysis, and statistically significant factors in univariate analysis were then included in multivariate analysis.Results In univariate analysis,Ann Arbor stage,performance status,IPI,number of extra-lymphatic site,B symptoms,LDH and β-MG level.were found to be the prognostic factors associated with time to overall survival in nasal type NKTCL.In multivariate analysis, Ann Arbor stage,performance status,LDH and β2-MG level were independent prognostic factors of overall survival.Conclusion Ann Arbor stage,performance status,LDH and β2-MG level were demonstrated as independent prognostic factors of the overall survival in nasal type NKTCL.

Objective Controversy exists over the effects of postoperative chemoradiotherapy or chemotherapy in the treatment of rectal cancer. This study aims to evaluate the clinical effect of chemoradiotherapy or chemotherapy following radical surgery for stage Ⅱ-Ⅲrectal cancer. Methods We retrospectively analyzed the clinical data of 125 cases of stageⅡ-Ⅲrectal cancer receiving chemo-radiotherapy ( n=69) or chemotherapy ( n=56) after radical surgery. The patients in the chemoradiotherapy group were treated by 3-di-mensional conformal or intensity-modulated radiotherapy at a total irradiation dose of 45-50 Gy/25-28 times and concurrently by XE-LOX/FOLFOX chemotherapy for 4-6 cycles. Those in the chemotherapy group underwent XELOX/FOLFOX chemotherapy only, at the same dose and for the same length of time as the former. Results The therapeutic effect on stageⅡ-Ⅲrectal cancer was not correla-ted with the gender, family history, smoking history, drinking history, high-fat intake, sedentariness, obesity or constipation of the pa-tient, nor with the TNM stage, pathological grade or differentiation degree of the disease. The 1-, 2-, and 3-year survival rates were sig-nificantly higher in the chemoradiotherapy group (86. 9%, 76. 8%, and 57. 9%) than in the chemotherapy group (71. 4%, 58. 9%, and 39. 3%) (P<0. 05), while the 1-, 2-, and 3-year recurrence rates were remarkably lower in the former (5. 8%, 11. 6%, and 18. 8%) than in the latter (17. 9%, 26. 8%, and 37. 5%) (P<0. 05). Statistically significant differences were found between the che-moradiotherapy and chemotherapy groups in the incidence of diarrhea (39. 1%vs 14. 3%, P<0. 05), but not in such adverse reactions as bone marrow suppression, nausea, or vomiting (P>0. 05). Conclusion For stageⅡ-Ⅲrectal cancer, postoperative chemoradio-therapy is a safe and effective option , which can evidently reduce local recurrence and improve 3-year survival of the patient.

Objective To explore the clinical significance of plasma D-dimer level before and after chemotherapy in patients with malignant lymphoma.Methods 402 patients admitted to Tianjin Medical University Cancer Institute and Hospital and pathologically diagnosed with malignant lymphoma were retrospectively analyzed to investigate the relationship between patients' plasma D-dimer level and their clinic pathology.Meanwhile,the association between patients' plasma D-dimer level change after chemotherapy and therapeutic effect was also evaluated.Results The median plasma D-dimer levels in malignant lymphoma patients (734.51ng/ml) was distinctly higher than that in normal population (＜500 ng/ml).The plasma D-dimer level had obvious correlation with age,pathological type,level of LDH,clinical stage,B symptom and IPI score.The level of plasma D-dimer in positive response group significantly decreased from 949.40 ng/ml to 499.88 ng/ml after chemotherapy (P ＜ 0.05),whereas that in the negtive response group significantly increased from 611.09 ng/ml to 899.76 ng/ml (P ＜ 0.05).Conclusion The level of plasma D-dimer may provide the basis for evaluating the chemotherapeutic effect in patients with malignant lymphoma.

Objective:This study was conducted to evaluate and discuss the curative effect and toxicity of gemcitabine, navel-bine, and therarubicin (GNT) regimen for patients with refractory or relapsed T-cell lymphoma (TCL). Methods:A total of 69 patients with refractory or relapsed TCL treated with GNT were enrolled. The treatment protocol was set as follows:800 mg/m2 gemcitabine ad-ministered at 1 and 8 d;25 mg/m2 navelbine administered at 1 d;and 20 mg/m2 therarubicin administered at 1 d. This protocol was re-peated every three weeks. The median cycle was 4 (range:2 to 6). Results:The overall response rate was 65.2%and the achieved com-plete remission was 29.0%. Hematology toxicities were the main adverse reactions observed in all of the patients. The incidence rates of grades 1 and 2 toxicity in leukopenia or neutropenia, anemia, and thrombocytopenia were 50.7%, 33.3%, and 26.1%, respectively. Grades 3 and 4 treatment-associated toxicities were detected in 23.1%of the responding patients. One-, three-, and five-year estimated overall survival (OS) of the whole cohort were 71.7%, 47.3%, and 32.4%, respectively. The median OS was 36 months. Conclusion:GNT was effective and suitable for patients with refractory or relapsed TCL.

Objective Confirmatory Factor Analysis(CFI)to the adolescent family Satisfaction Scale (AFSS).Methods Investigated 1306 subjects aged from 12 to 23 year old adolescent at school,used of CFI and cross-validation to confirm AFSS structure.Results Obtained revised structure of 3 factors and 23 items,AFSS including 10 items interpersonal atmosphere,7 items parental and children emotional interaction,6 items management style.Fit index X2/df less than 5,RMSEA less than 0.08,GFI,NFI,TFI,IFI more than 0.9,cross-validation and reliability were better.Conclusion The adolescent family satisfaction is first-order structure including three factors,AFSS is a reliable and validity scale for assessing the family satisfaction of adolescents.

Objective To investigate the mental health of the frequent hit-and-run driver,and to explore its relationship with their life events and personality.Methods Stratified cluster sampling method was used to draw 870 motor vehicle drivers,and chose the 620 met the study conditions.They were investigated by the demographic questionnaire,life event scale,symptom check list-90(SCL-90)and eysenck personality questionnaire (EPQ).Results (1)The SCL-90 total score and the factor scores of the accident group were significantly higher than the non-accident group(respectively,65.17±39.68 vs 18.65±13.85,9.24±5.44 vs 3.48±2.84,6.96±4.81 vs 1.83±2.11,10.19±7.19 vs 2.53±2.74,7.00±4.96 vs 1.48±1.77,4.68±3.66 vs 1.24±1.48,3.51±3.58 vs 0.62±1.29,3.84±3.36 vs 1.00±1.33,5.34±4.17 vs 1.27±1.72,8.93±6.54 vs 2.96±2.97,6.08±4.81 vs 2.11±2.18),the differences were significant(P＜0.01).(2)The related analysis showed there existed the statistically positive relation between the total scores of SCL-90 and the factors of the life event scale and EPQ expect for the sense of concealing factor(r=0.146～0.393,P＜0.05).(3)Analysis of regression showed the factors of life event and personality had different influences on total scores and factor scores of SCL-90,and negative life events were the most important predictor of SCL-90 total score of frequent hit-and-run driver.Conclusion There are many mental problems among the frequent hit-and-run drivers.Life events,mood and psychoticism factors of personality are important influencing factor to their mental health.

Objective To explore the clinicopathological characteristics of lupus nephritis (LN) with antinucleosome antibody (AnuA).Methods Data of 481 patients with biopsy-proven LN in the First Affiliated Hospital of Zhengzhou University from 2004 to 2011 were analyzed retrospectively.The patients were divided into two groups:AnuA-positive group (76 patients) and AnuA-negative group (405 patients).The clinical manifestations,laboratory examinations,histopathologic classes of LN,disease activity measured by SLE disease activity index (SLEDAI) of two groups were investigated and compared.Results There were 15 male patients in positive group (15/76,19.74％) with mean age of (27.99±10.88) years and 45 patients in negative group (45/405,11.11％) with mean age of (31.15±12.15) years respectively,which showed that male patients were more common in positive group (P＜0.05).Incidences of oral ulcer,fever,anemia,low complement and positive anti-dsDNA antibody were higher in positive group (P＜0.05).Percentage of diffuse proliferative lupus nephritis (class Ⅳ ) and pathological activity index (AI) in positive group were higher compared to negative group (all P＜0.05),while no significant differences of other pathological types,chronic index (CI) and SLEDAI were found between two groups.Conclusion LN patients with positive AnuA have special clinicopathological characteristics and AnuA may be used as a promising biomarker for the proliferative LN.

Primary testicular lymphoma comprises 1% to 9% of testicular neoplasms and represents 1% to 2% of all non-Hodg-kin lymphomas. Histologically, the majority of the tumor consists of diffuse large B-cell non-Hodgkin lymphomas that are of intermedi-ate- or high-grade neoplasm. Clinically, the disease typically presents as a painless testicular swelling that develops over a span of weeks to months. B symptoms such as fever, weight loss, and anorexia are present in 25% to 41% of the patients. This tumor is an ag-gressive type, with frequent invasion of the epididymis, spermatic cord, and scrotum, as well as a marked tendency to relapse, especial-ly in the CNS. The treatment is mainly based on orchiectomy (mostly in stages ⅠE and ⅡE) regardless of its association with prophy-lactic irradiation of the scrotum and administration of intrathecal chemotherapy, cyclophosphamide, doxorubicin, vincristine, and pred-nisone regimen chemotherapy plus rituximab (R-CHOP) (stages ⅢE and ⅣE) and radiotherapy. The multi-modality treatment marked-ly improved progression-free and overall survival. We introduce as reference one case that received a multidisciplinary comprehensive discussion in the Department Lymphoma, Tianjin Medical University Cancer Hospital.